VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+11.92%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$191M
AUM Growth
-$59.3M
(-24%)
Cap. Flow
-$77.9M
Cap. Flow
% of AUM
-40.7%
Top 10 Holdings %
Top 10 Hldgs %
5.8%
Holding
489
New
53
Increased
164
Reduced
226
Closed
46
Top Buys
| 1 |
D.R. Horton
DHI
|
$987K |
| 2 |
Lennar Class A
LEN
|
$952K |
| 3 |
Freeport-McMoran
FCX
|
$917K |
| 4 |
TJX Companies
TJX
|
$909K |
| 5 |
Ametek
AME
|
$905K |
Top Sells
| 1 |
Steel Dynamics
STLD
|
$1.65M |
| 2 |
NOA
North American Construction
NOA
|
$1.55M |
| 3 |
Alamos Gold
AGI
|
$1.53M |
| 4 |
Cheniere Energy
CQP
|
$1.51M |
| 5 |
GTY
Getty Realty Corp
GTY
|
$1.5M |
Sector Composition
| 1 | Healthcare | 26.88% |
| 2 | Financials | 12.6% |
| 3 | Technology | 10.15% |
| 4 | Materials | 9.55% |
| 5 | Real Estate | 8.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
401
Immatics
IMTX
$718M
| $126K | 0.07% |
+14,500
| New | +$126K |
|
402
Arcturus Therapeutics
ARCT
$490M
| $126K | 0.07% |
7,431
-661
| -8% | -$11.2K |
|
403
Intellia Therapeutics
NTLA
$1.26B
| $126K | 0.07% |
3,610
+890
| +33% | +$31.1K |
|
404
PMV Pharmaceuticals
PMVP
$73.1M
| $125K | 0.07% |
14,425
+3,364
| +30% | +$29.3K |
|
|
AGEN
405
Agenus
AGEN
$135M
| $125K | 0.07% |
2,653
-1,441
| -35% | -$67.9K |
|
406
Erasca
ERAS
$437M
| $125K | 0.07% |
28,940
+7,453
| +35% | +$32.1K |
|
407
Arcutis Biotherapeutics
ARQT
$1.98B
| $125K | 0.07% |
8,423
+3,148
| +60% | +$46.6K |
|
408
Precigen
PGEN
$1.36B
| $125K | 0.07% |
81,912
-3,706
| -4% | -$5.63K |
|
409
Nurix Therapeutics
NRIX
$719M
| $124K | 0.07% |
11,332
+519
| +5% | +$5.7K |
|
410
Cullinan Oncology
CGEM
$406M
| $124K | 0.06% |
11,751
+3,065
| +35% | +$32.3K |
|
411
Biohaven
BHVN
$1.73B
| $124K | 0.06% |
+8,916
| New | +$124K |
|
|
AMRS
412
DELISTED
Amyris Inc.
AMRS
| $122K | 0.06% |
79,585
+22,815
| +40% | +$34.9K |
|
413
Rocket Pharmaceuticals
RCKT
$349M
| $120K | 0.06% |
6,154
-3,706
| -38% | -$72.5K |
|
|
IGMS
414
DELISTED
IGM Biosciences
IGMS
| $120K | 0.06% |
7,078
-241
| -3% | -$4.1K |
|
415
ATAI Life Sciences
ATAI
$956M
| $120K | 0.06% |
45,184
+12,843
| +40% | +$34.2K |
|
416
Arbutus Biopharma
ABUS
$797M
| $120K | 0.06% |
51,496
+8,508
| +20% | +$19.8K |
|
417
Editas Medicine
EDIT
$231M
| $120K | 0.06% |
13,520
+3,080
| +30% | +$27.3K |
|
|
VERV
418
DELISTED
Verve Therapeutics
VERV
| $120K | 0.06% |
+6,195
| New | +$120K |
|
419
Relay Therapeutics
RLAY
$683M
| $120K | 0.06% |
8,004
+478
| +6% | +$7.14K |
|
420
Atara Biotherapeutics
ATRA
$88M
| $118K | 0.06% |
1,444
+634
| +78% | +$52K |
|
421
Recursion Pharmaceuticals
RXRX
$1.98B
| $118K | 0.06% |
15,342
-1,505
| -9% | -$11.6K |
|
422
Kymera Therapeutics
KYMR
$3.08B
| $118K | 0.06% |
4,729
-2,493
| -35% | -$62.2K |
|
423
CureVac
CVAC
$1.21B
| $118K | 0.06% |
19,535
+11,802
| +153% | +$71.2K |
|
424
Adicet Bio
ACET
$58.7M
| $118K | 0.06% |
13,164
+3,912
| +42% | +$35K |
|
425
Dyne Therapeutics
DYN
$1.97B
| $118K | 0.06% |
+10,150
| New | +$118K |
|